<DOC>
	<DOC>NCT02955121</DOC>
	<brief_summary>Randomized controlled study to examine physician use of pharmacogenetic information in patients receiving antiplatelet medication after percutaneous coronary intervention (PCI).</brief_summary>
	<brief_title>IU Health Krannert Personalized Medicine Study</brief_title>
	<detailed_description>The study will randomize patients who have completed PCI and who are prescribed dual antiplatelet therapy to a genotype guided arm, in which CYP2C19 pharmacogenetic testing will be performed and a standard therapy arm without genetic testing. The study will examine the impact of pharmacogenetic testing on physician medication choice and clinical outcomes.</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<criteria>Patients with ischemic heart disease, who are prescribed dual antiplatelet therapy after percutaneous coronary intervention (PCI). Enrollment has to occur during index hospitalization or during outpatient visit for cath lab procedure. Pregnant or breastfeeding. Unwilling or unable, in the opinion of the investigator, to comply with instructions on prescribed medicines. Prior known allergy or intolerance to clopidogrel.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Cytochrome P-450 CYP2C19</keyword>
	<keyword>Pharmacogenetics</keyword>
	<keyword>Platelet Aggregation Inhibitors</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
</DOC>